Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis
23.12.2021 17:06:00 EET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences Limited to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialised from 2026 in Europe, the UK, Switzerland, and Australia.
Theramex’s Tocilizumab product will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors. The reference product RoActemra® is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate; moderate to severe RA adult patients who have not responded well/intolerant to DMARDs or Anti-TNFs; active systemic juvenile idiopathic arthritis in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids; juvenile idiopathic polyarthritis in patients 2 years of age and older unresponsive to MTX; treatment of Giant Cell Arteritis in adults; and chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
“Rheumatoid arthritis affects more women than men, so the addition of this biosimilar drug to our existing Rheumatology portfolio continues our strategic determination to improve access and affordability of important treatments for women. We are excited to expand our focus in Rheumatology to now include rheumatoid arthritis to help even more patients with bone diseases and joint pain”, said Theramex CEO Robert Stewart .
Dr. Himanshu Gadgil, Enzene's Whole Time Director said, "The development of Enzene’s Tocilizumab, through our innovative efforts in the manufacturing of monoclonal antibodies, marks another highlight in a series of endeavours driven by our mission to provide affordable and expanded access to crucial medicines. Our partnership with Theramex bolsters our mission to bring affordable healthcare to patients across the world”.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company, a subsidiary of Alkem Laboratories Ltd. (One of the top five pharmaceutical companies in India*) located in Pune, India. Enzene's focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services.
(*as per the latest IQVIA data of MAT July 2021)
For more information on Enzene Biosciences Ltd., please visit www.enzene.com
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
1 https://www.nhs.uk/conditions/rheumatoid-arthritis/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005258/en/
Contact information
Theramex
Jesús López | Associate Director, Communication & Digital | Jesus.Lopez@Theramex.com
Enzene Biosciences Ltd.
For media enquiries,
Dr. Tarun Chawla
Head - Business Development & Business Operations
Enzene Biosciences Ltd.
For any further enquiries, please reach out to: bd@enzene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ScottsMiracle-Gro Cultivates End-to-End Supply Chain Agility with Kinaxis22.6.2026 14:00:00 EEST | Press release
Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that ScottsMiracle-Gro, the leading marketer of branded consumer lawn and garden products in North America, is expanding its partnership with Kinaxis. The move will further optimize its supply chain planning operations as part of a broader transformation initiative, building on proven success and results achieved in recent years. Operating in a seasonal environment, where demand can be impacted by regional weather patterns, retailer promotions, and shifting consumer behavior, ScottsMiracle-Gro is investing further in the Kinaxis Maestro™ platform to improve planning accuracy and strengthen end-to-end supply chain orchestration across its North American network. This transformation reflects the company’s focus on supply chain technology as a foundational necessity. By connecting planning, decision-making, and execution on a unified platform, the company aims to improve responsiven
NIQ Expands GeoPurchase Audiences Globally, Unlocking Growth Opportunities for Marketers in Poland, Belgium, Mexico, and Indonesia22.6.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its GeoPurchase audiences into Poland, Belgium, Mexico, and Indonesia, extending its purchase-based, geo-targeted audiences to new international markets. As privacy regulations tighten and identifiers like cookies decline, marketers need new ways to reach high-value consumers at scale. NIQ’s GeoPurchase Audiences address this challenge by helping marketers identify and target consumers based on demand, not just demographics. GeoPurchase audiences help marketers pinpoint geographic areas where consumers are most likely to purchase specific FMCG categories, brands, or sub-brands, so media investments can concentrate where retail opportunities are strongest. By focusing investments in priority locations, marketers can connect with the audiences that matter in the markets with the greatest opportunity. As a result, GeoPurchase audiences help marketers improve media efficiency by turning local demand
Smartly Introduces Smartly Synapse, the Intelligent AI Orchestration Layer Powering Its Advertising Platform22.6.2026 13:00:00 EEST | Press release
Smartly today introduced Smartly Synapse, the intelligent AI orchestration and memory layer behind every Smartly AI Agent. Built on years of cross-channel creative, media and performance intelligence and continuously shaped by real-world outcomes, Smartly Synapse transforms millions of signals into actions that help marketers plan smarter, execute faster and drive stronger business results. Smartly Synapse creates a continuous performance loop where marketer intent, business context, campaign activity and outcomes continuously inform one another. Its shared intelligence and memory layer helps the system learn from every campaign, improving future recommendations, execution and performance. “Smartly Synapse is the intelligent AI orchestration and memory layer behind our AI agents. It augments Smartly’s existing platform, turning campaign data, business context and user input into coordinated action,” said Maxwell Tang, Chief Product Officer, Smartly. “We built Smartly Synapse for brands
Europe’s Original First Check Investor Seedcamp Raises $320 Million22.6.2026 12:23:00 EEST | Press release
Seedcamp, Europe’s original first check investor and earliest backer of companies including Revolut, Wise, UiPath, Synthesia and Fluidstack, has raised $320 million to invest in the next generation of global companies. US expansion for born global founders and early growth capital for portfolio winners Since launching in 2007 with a $2.5m first fund, Seedcamp now manages over $1bn in AUM and has delivered some of the strongest venture fund returns in Europe. Seedcamp Fund III has now returned over 13x DPI to its Limited Partners, and Fund IV sits at over 5x net TVPI. The new capital is allocated between $220m for Seedcamp VII, the flagship first check fund, and $100m for the Select fund, which focuses primarily on backing portfolio winners as they scale toward Series B and beyond. For nearly two decades, Seedcamp has backed founders before they become obvious as the first institutional investor. Many of those companies have gone on to become the largest technology businesses in the wor
Navan Invests in European Footprint with New Partnerships22.6.2026 11:01:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced new integrations with European travel suppliers. Navan will add to its platform a direct New Distribution Capability (NDC) connection with Italy’s national air carrier, ITA Airways; overnight rail services in the UK with Caledonian Sleeper; and mobile-first car rental bookings in France with Virtuo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622904121/en/ New integrations with ITA Airways, Caledonian Sleeper, and Virtuo elevate localized inventory across Europe “We’re seeing incredible momentum across Europe, bookings to and from the continent are up year-over-year, and to truly serve the European market you have to continually invest locally,” said Michael Riegel, Chief Customer Officer at Navan. “By bringing ITA’s NDC, Virtuo, and Caledonian Sleeper cabins to Navan, we’re working to make sure European businesses have al
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom